Table 2 Characteristics of the study population stratified by median RTEs, RTE%, CD28−/CD4+, and CD28−/CD4+
From: Decreased thymic output predicts progression of chronic kidney disease
Variable | All | RTEs | RTE% | CD28−/CD4+ | CD28−/CD8+ | ||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Low | High | Low | High | Low | High | Low | High | |
Range |  | 7.5–97.5 | 97.6–537.6 | 1.8–16.2 | 16.3–53.7 | 0–5.3 | 5.4–56.0 | 3.3–49.7 | 49.8–88.6 |
N | 175 | 88 | 87 | 88 | 87 | 75 | 74 | 87 | 86 |
Age (years) | 73 [62, 79] | 77 [71, 82] | 68 [53, 76] | 76 [71, 82] | 68 [57, 76] | 73 [63, 79] | 76 [69, 82] | 72 [55, 79] | 75 [68, 81] |
Sex (female), n (%) | 58 (33) | 21 (24) | 37 (43) | 22 (25) | 36 (41) | 16 (21) | 26 (35) | 26 (30) | 31 (36) |
Diabetes, n (%) | 80 (46) | 50 (57) | 30 (34) | 55 (63) | 25 (29) | 41 (55) | 29 (39) | 41 (47) | 38 (44) |
Cardiovascular disease, n (%) | 43 (25) | 31 (35) | 12 (14) | 29 (33) | 14 (16) | 21 (28) | 20 (27) | 20 (23) | 23 (27) |
Hypertension, n (%) | 154 (88) | 79 (90) | 75 (86) | 79 (90) | 75 (86) | 72 (96) | 66 (89) | 75 (86) | 78 (91) |
BMI (kg/m2) | 23.9 [21.1, 25.8] | 23.8 [21.4, 25.5] | 24.1 [21.0, 26.3] | 24.0 [21.8, 26.1] | 23.4 [20.8, 25.6] | 23.9 [22.1, 25.5] | 24.3 [22.1, 26.4] | 23.9 [20.9, 26.1] | 23.9 [21.8, 25.5] |
Chronic glomerulonephritis, n (%) | 47 (27) | 16 (18) | 31 (36) | 17 (19) | 30 (34) | 13 (17) | 18 (24) | 27 (31) | 18 (21) |
Diabetic nephropathy, n (%) | 54 (31) | 35 (40) | 19 (22) | 36 (41) | 18 (21) | 27 (36) | 21 (28) | 26 (30) | 28 (33) |
Nephrosclerosis, n (%) | 45 (26) | 28 (32) | 17 (20) | 28 (32) | 17 (20) | 24 (32) | 20 (27) | 20 (23) | 25 (29) |
Others, n (%) | 29 (17) | 9 (10) | 20 (23) | 7 (8) | 22 (25) | 11 (15) | 15 (20) | 14 (16) | 15 (17) |
Current smoking, n (%) | 27 (16) | 12 (14) | 15 (17) | 15 (18) | 12 (14) | 14 (19) | 10 (14) | 15 (18) | 12 (14) |
Use of ACE-inhibitor or ARB, n (%) | 100 (57) | 49 (56) | 51 (59) | 52 (59) | 48 (55) | 43 (57) | 42 (57) | 48 (55) | 51 (59) |
CMV seropositive, n (%) | 164 (94) | 85 (97) | 79 (92) | 85 (97) | 79 (92) | 70 (93) | 73 (100) | 78 (90) | 85 (100) |
eGFR (mL/min/1.73 m2) | 26 [16, 40] | 22 [13, 32] | 32 [22, 48] | 23 [14, 33] | 31 [17, 47] | 26 [15, 37] | 26 [18, 36] | 29 [15 42 | 26 [16, 34] |
CKD stage 1 or 2, n (%) | 14 (8) | 3 (3) | 11 (13) | 2 (2) | 12 (14) | 3 (4) | 3 (4) | 10 (11) | 3 (3) |
CKD stage 3, n (%) | 61 (35) | 23 (26) | 38 (44) | 26 (30) | 35 (40) | 27 (36) | 25 (34) | 32 (37) | 28 (33) |
CKD stage 4, n (%) | 60 (34) | 34 (39) | 26 (30) | 36 (41) | 24 (28) | 26 (35) | 32 (43) | 26 (30) | 34 (40) |
CKD stage 5, n (%) | 40 (23) | 28 (32) | 12 (14) | 24 (27) | 16 (18) | 19 (25) | 14 (19) | 19 (22) | 21 (24) |
Urinary protein (g/gCr) | 1.25 [0.40, 2.83] | 1.60 [0.60, 3.41] | 0.82 [0.24, 2.67] | 1.72 [0.55, 3.60] | 0.83 [0.28, 1.96] | 1.25 [0.32, 3.03] | 1.23 [0.49, 2.66] | 1.25 [0.34, 3.24] | 1.26 [0.48, 2.68] |
Hemoglobin (g/dL) | 12.1 [10.7, 13.7] | 11.2 [10.5, 13.2] | 12.6 [11.4, 14.0] | 11.5 [10.5, 13.4] | 12.4 [10.9, 14.0] | 11.7 [10.6, 13.7] | 12.4 [11.0, 14.0] | 12.1 [10.7, 13.6] | 12.1 [10.6, 13.9] |
Serum albumin (g/dL) | 4.0 [3.6, 4.2] | 3.9 [3.5, 4.1] | 4.1 [3.6, 4.3] | 3.9 [3.4, 4.2] | 4.0 [3.6, 4.3] | 4.0 [3.7, 4.2] | 4.0 [3.7, 4.3] | 4.0 [3.5, 4.3] | 3.9 [3.6, 4.2] |
Serum C-reactive protein (mg/dL) | 0.07 [0.04, 0.13] | 0.08 [0.03, 0.12] | 0.07 [0.04, 0.14] | 0.07 [0.04, 0.15] | 0.07 [0.04, 0.15] | 0.07 [0.04, 0.11] | 0.07 [0.03, 0.13] | 0.07 [0.04, 0.11] | 0.08 [0.03, 0.15] |